ReQoL Community of Practice Event – 17th October, Sheffield UK
Sharing learning and knowledge about how ReQoL can be used to support person-centred, recovery-focused mental health services.
BioJapan 2019
Catch up with the latest developments from the Clinical Outcomes team at BioJapan 2019 in Pacifico Yokohama, from the 9th - 11th October.
The Clinical Outcomes team will be attending The International Congress of Parkinson’s Disease and Movement Disorders®
Dr David Churchman to represent the Clinical Outcomes team at the International Congress of Parkinson’s Disease and Movement Disorders, Nice, France, from the 22nd - 26th September 2019.
ISPOR seeking input for discussions on developing “guiding principles” for COAs in real-world studies!
ISPOR Clinical Outcome Assessment Special Interest Group will be hosting a virtual roundtable meeting to examine ISPOR members’ opinions on developing guiding principles for the use of COAs in real world studies.
The Oxford Participation and Activities Questionnaire (OxPAQ) – Further validation for use in three more conditions
The generic Patient Reported Outcome (PRO) measure – the Oxford Participation and Activities Questionnaire (OxPAQ) has been further validated for use in three more common conditions.
The Oxford Participation and Activities Questionnaire (OxPAQ) – Minimal Important Differences (MID) and effect sizes are now available!
Minimal Important Difference (MID) and Effect Sizes for the measure’s domains now available
The PROMS Annual Research Conference 2019
Oxford University Innovation's Clinical Outcome team will be attending the annual PROMS research conference in Leeds, UK on the 13th June 2019.
ISPOR 2019 New Orleans
Oxford University Innovation's Clinical Outcome team will be attending the annual ISPOR conference in New Orleans, LA from the 18th - 22nd May 2019.
Producing QALY’s: Diabetes-specific preference-based measures for health economics and outcomes research
The Clinical Outcomes team at Oxford University Innovation are very pleased to announce the availability of diabetes-specific preference-based measures that can be used to produce valuable health economic data.
The Oxford Participation and Activities Questionnaire (OxPAQ) has now been validated for other conditions
The OxPAQ is now validated for use in Chronic obstructive pulmonary disease (COPD), Aneurysmal subarachnoid haemorrhage (AHS) and Valvular heart disease.
© Oxford University Innovation